Evidence map›Paper›PMID 30126163›Full record

ReviewInternational journal of environmental research and public health2018

Vitamin D Deficiency in Chronic Kidney Disease: Recent Evidence and Controversies.

Pedro Henrique Franca Gois, Martin Wolley, Dwarakanathan Ranganathan, Antonio Carlos Seguro

Open access · goldAbstract readReview
In one paragraph

Review in International journal of environmental research and public health, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 2 pooled it
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 2 syntheses or guidelines pooled it, 118 citations in OpenAlex.

  1. Pooled it
  2. Osteoporosis in Patients with Chronic Kidney Diseases: A Systemic Review.International journal of molecular sciences · 2020
    Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Population Pharmacokinetic Model of Vitamin DInternational journal of molecular sciences · 2024
    Article
  14. Article
  15. Vitamin D: A Bridge between Kidney and Heart.Life (Basel, Switzerland) · 2024
    Review
  16. Review
  17. Observational
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Pedro Henrique Franca GoisKidney Health Service, Royal Brisbane and Women's Hospital, Herston QLD 4029, Australia. pedro.francagois@health.qld.gov.au.
Martin WolleyKidney Health Service, Royal Brisbane and Women's Hospital, Herston QLD 4029, Australia. martin.wolley@health.qld.gov.au.
Dwarakanathan RanganathanKidney Health Service, Royal Brisbane and Women's Hospital, Herston QLD 4029, Australia. dwarakanathan.ranganathan@health.qld.gov.au.
Antonio Carlos SeguroLaboratory of Medical Research-LIM12, Nephrology Department, University of São Paulo School of Medicine, São Paulo, CEP 01246-903, Brazil. trulu@usp.br.
Royal Brisbane and Women's Hospital · AUUniversidade de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vitamin D (VD) is a pro-hormone essential for life in higher animals. It is present in few types of foods and is produced endogenously in the skin by a photochemical reaction. The final step of VD activation occurs in the kidneys involving a second hydroxylation reaction to generate the biologically active metabolite 1,25(OH)₂-VD. Extrarenal 1α-hydroxylation has also been described to have an important role in autocrine and paracrine signaling. Vitamin D deficiency (VDD) has been in the spotlight as a major public healthcare issue with an estimated prevalence of more than a billion people worldwide. Among individuals with chronic kidney disease (CKD), VDD prevalence has been reported to be as high as 80%. Classically, VD plays a pivotal role in calcium and phosphorus homeostasis. Nevertheless, there is a growing body of evidence supporting the importance of VD in many vital non-skeletal biological processes such as endothelial function, renin-angiotensin-aldosterone system modulation, redox balance and innate and adaptive immunity. In individuals with CKD, VDD has been associated with albuminuria, faster progression of kidney disease and increased all-cause mortality. Recent guidelines support VD supplementation in CKD based on extrapolation from cohorts conducted in the general population. In this review, we discuss new insights on the multifactorial pathophysiology of VDD in CKD as well as how it may negatively modulate different organs and systems. We also critically review the latest evidence and controversies of VD monitoring and supplementation in CKD patients.

Indexed as

AnimalsBone DensityDiabetes MellitusDietary SupplementsDisease ProgressionEndotheliumHumansKidneyMuscle, SkeletalNutritional StatusOxidation-ReductionParathyroid HormonePrevalenceProteinuriaRenal Insufficiency, ChronicRenin-Angiotensin SystemParathyroid HormoneVitamin Dchronic kidney diseaseproteinuriaVitamin DVitamin D deficiency

Identifiers

PMID30126163
PMCPMC6121405
OpenAlexW2884274719

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.